Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06147505
Other study ID # XS-005
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 29, 2023
Est. completion date December 29, 2025

Study information

Verified date November 2023
Source Dushu Lake Hospital Affiliated to Soochow University
Contact Yulun Huang
Phone +86 130 1388 9432
Email huangyulun@suda.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of this clinical study is to evaluate the safety of XS005 cell which contains Natural Killer (NK) cells and culture-expanded injection; to determine the maximum tolerated dose . Furthermore, initial efficacy will be examined.


Description:

Treatment on this study includes eight XS005 cell infusions over an 16 week period. The study will evaluate the safety, feasibility and maximum tolerated dose (MTD) of XS005 cell using a 3+3 study design . The total study duration will be 2 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 29, 2025
Est. primary completion date November 2, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Age between 18 and 70 years old (including the threshold), both male and female; 2. GBM (2021 5th Edition of World Health Organization(WHO) Classification of Central nervous System Tumors) diagnosed for the first time by imaging and histopathology; 3. Expected survival =6 months; 4. Karnofsky performance status(KPS) score =60 before treatment; 5. The level of organ and bone marrow function must meet the following requirements: - Bone marrow: Absolute neutrophil count (ANC) =1.5×109/L, platelet count =100×109/L, hemoglobin =90g/L, and no platelet or red blood cell transfusion within 14 days prior to first administration. And did not receive blood transfusion or biological response regulators (such as granulocyte growth factor, erythrocyte growth factor, interleukin-11, etc.) within 14 days before the first administration; - Liver function: No history of cirrhosis (Child-Pugh grade B, C). Serum total bilirubin (TBIL) =1.5× upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5×ULN; - Renal function: serum creatinine =1.5×ULN, or creatinine clearance =50ml/min (Cockcroft-Gault formula); Qualitative urine protein =1+; If the qualitative urine protein is =2+, it is necessary to conduct a quantitative urine protein test for 24 hours. According to the examination results, the researchers made the admission judgment. - Coagulation function: prothrombin time (PT) =1.5×ULN; International standardized ratio (INR) =1.5×ULN, and activated partial thromboplastin time (APTT) =1.5×ULN (except those receiving therapeutic anticoagulants); 6. The subjects (including male subjects) have no pregnancy plan and voluntarily take effective contraceptive measures during the screening period and from the beginning of the study administration to the last dose of the study drug within 6 months after the study drug is administered, and have no sperm or egg donation plans, in which the study period should voluntarily take effective contraceptive measures; 7. Able to understand the procedures and methods of this study, willing to sign informed consent and strictly follow the clinical study protocol to complete this study. Exclusion Criteria: 1. Patients who received other anti-tumor drugs (including chemotherapy, targeted drugs other than bevacizumab, immunotherapy, Chinese medicine anti-tumor therapy, etc.) except for patients who received concurrent radiotherapy and chemotherapy for GBM after surgery (TMZ dosage =75mg/m2, radiotherapy dose limited to 50-60Gy); 2. Previous or current malignant tumors of other types, except for the following cases: basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin or cervical cancer in situ; 3. Known to be allergic to dacarbazine, temozolomide, the investigational drug, or any of its excipients, or has had a history of unexplained severe allergic reactions; 4. The presence of any contraindications to MRI, such as: use of a pacemaker, infusion pump, or allergy to MRI contrast agents; 5. Receive live attenuated vaccine or vaccine within 4 weeks prior to the first study drug treatment or plan to receive live vaccine during the study period; 6. Subjects with active or pre-existing autoimmune diseases that are likely to recur, or patients at high risk (such as those who have received an organ transplant and require immunosuppressive therapy). 7. Severe cardiovascular and cerebrovascular diseases within 6 months before screening; 8. Patients with sudden lung disease, interstitial lung disease or pneumonia, pulmonary fibrosis, acute lung disease, etc., which cannot be controlled after treatment, except local interstitial pneumonia induced by radiotherapy; 9. A history of infection with human immunodeficiency virus, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or stem cell transplantation; Except for those that do not require immunosuppressive therapy, such as corneal transplantation; 10. Evidence of active infection: 1. Hepatitis B (with hepatitis B surface antigen(HBsAg) positive, hepatitis B virus-DNA(HBV-DNA)=500IU/ml and abnormal liver function); 2. Hepatitis C (hepatitis C antibody( HCV-Ab) positive, hepatitis C virus-RNA(HCV-RNA) higher than the lower limit of assay and abnormal liver function); 3. Patients with active pulmonary tuberculosis infection found through medical history or CT examination, or a history of active pulmonary tuberculosis infection within 1 year before enrollment, or a history of active pulmonary tuberculosis infection more than 1 year ago without formal treatment; 11. Have a clear history of neurological or psychiatric disorders, or a known history of psychotropic substance abuse, alcohol abuse, or drug use; 12. Received any investigational drug within 4 weeks prior to initial dosing, or participated in another clinical study at the same time; 13. Women who are pregnant or breastfeeding, or who have a positive baseline pregnancy test; 14. Patients deemed unsuitable for inclusion in this study by the investigators.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
XS005 Cell Injection
Treatment on this study includes eight XS005 cell infusions over an 16 week period. Phase 1: dose escalation (3+3); Phase 2 : dose of recommended phase 2 dose(RP2D).
Drug:
Temozolomide(TMZ)
Patients were given temozolomide on day 1 to day 5 of each cycle, 28 days per cycle, for a total of 4 cycles.

Locations

Country Name City State
China Dushu Lake Hospital Affiliated to Soochow University Suzhou Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Dushu Lake Hospital Affiliated to Soochow University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of natural killer (NK ) cells in cerebrospinal fluid(CSF). Changes of NK cells in CSF pre-and post- infusion and at each of the main follow-up time points. Day 2 to day 9 of each treatment cycle(each treatment cycle is 28 days).
Other Changes of cytokines in CSF. Changes of cytokines (such as interleukin-6(IL-6), interferon-? (IFN-?) etc.) in CSF pre-and post- infusion and at each of the main follow-up time points. Day 2 to day 9 of each treatment cycle(each treatment cycle is 28 days).
Primary Incidence of Dose-Limiting Toxicities (DLTs) DLT is defined as a toxic effect in the subject at any dose, cannot be reasonably attributed to the subject's underlying disease, other conditions, and/or concomitants, that the investigator determines to be related (including definitely, likely, or possibly) to the XS005 cell injection. within 7 days after the the first infusion of XS005.
Primary Incidence of Adverse Events (AEs) AE is defined as any adverse medical event within 4 months after the the first infusion of XS005. 4 months
Primary Maximum tolerated dose (MTD) MTD is defined as the highest dose level of less than or equal to 2 DLT among the 6 subjects finally determined. within 7 days after the the first infusion of XS005.
Secondary Progression-free survival (PFS) PFS : defined as the time from the start of treatment until the onset of tumor progression or death from any cause; From the start of treatment until the time of first disease progression or death , assessed up to 12 months post-treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05664243 - A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Recruiting NCT05635734 - Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Terminated NCT03927222 - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Phase 2
Recruiting NCT03897491 - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma Phase 2
Active, not recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Completed NCT01922076 - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT04391062 - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma Phase 2
Active, not recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT02206230 - Trial of Hypofractionated Radiation Therapy for Glioblastoma Phase 2
Completed NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT03018288 - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Phase 2
Not yet recruiting NCT04552977 - A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Withdrawn NCT02876003 - Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma Phase 2